Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.

ABSTRACT:

Importance

A decision to initiate aspirin therapy for primary prevention of cardiovascular disease (CVD) requires consideration of both treatment benefits and harms. The most significant harm associated with aspirin is major bleeding, yet there is a paucity of data on bleeding risk in suitable community populations.

Objective

To determine the risk of major bleeding among people without CVD who are not receiving antiplatelet therapy.

Design, setting, and participants

Prospective cohort study of 359 166 individuals aged 30 to 79 years receiving primary care in New Zealand who had CVD risk assessment between 2002 and 2015. Participants were censored at the earliest date on which they had a first major bleeding event, died, or met any baseline cohort exclusion criteria or

SUBMITTER: Selak V 

PROVIDER: S-EPMC6583689 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature